MYC and Burkitt lymphoma: Other relevant results for the development of targeted strategies reveal that multi-drug-resistant Ph+ ALL harboring BCR-ABL1T315I is sensitive to STF-083010 treatment and that B-I09 was exceptionally effective against BL cells with high levels of Myc.